carotegrast methyl | 401905-67-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: carotegrast methyl
• 英文别名: methyl (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-[6-(dimethylamino)-1-methyl-2,4-dioxoquinazolin-3-yl]phenyl]propanoate
• CAS: 401905-67-7
• 化学式: C₂₈H₂₆Cl₂N₄O₅
• 分子量: 569.444
• InChiKey: MMHHPKCJJIFLBQ-QFIPXVFZSA-N

物化性质

• 密度：
  1.382±0.06 g/cm3(Predicted)
• 溶解度：
  DMSO：100 mg/mL（175.61 mM；需要超声波）

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  39
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  99.3
• 氢给体数：
  1
• 氢受体数：
  6

制备方法与用途

AJM300（包括AJM 300和AJM-300）是一种新型的选择性口服α4整合素拮抗剂，用于治疗活动性溃疡性结肠炎。

反应信息

• 作为反应物：
  描述：

  carotegrast methyl 在 甲醇 、 乙酰溴 作用下， 以10.5 g的产率得到
  参考文献：
  名称：

  EP2554542

  摘要：

  公开号：
• 作为产物：
  描述：

  Nα-(2,6-dichlorobenzoyl)-4-(6-dimethylamino-2,4[1H,3H]-quinazolinedione-3-yl)-L-phenylalanine methyl ester 生成 carotegrast methyl
  参考文献：
  名称：

  NEW PHENYLALANINE DERIVATIVES

  摘要：

  指定的苯丙氨酸衍生物及其类似物具有对α4整合素的拮抗作用。它们被用作治疗涉及α4整合素的各种疾病的治疗剂。

  公开号：

  US20120253041A1

文献信息

• METHODS FOR PRODUCING PHENYLALANINE DERIVATIVES HAVING A QUINAZOLINEDIONE SKELETON AND INTERMEDIATES FOR PRODUCTION THEREOF
  申请人：Kataoka Noriyasu

  公开号：US20100204505A1

  公开（公告）日：2010-08-12

  The present invention provides a method for producing a phenylalanine derivative(s) having a quinazolinedione ring of formula (5), including steps comprising of reacting an acylphenylalanine derivative(s) of formula (1) with a carbonyl group-introducing reagent(s) and a derivative(s) of anthranilic acid to form an asymmetric urea intermediate(s); making the asymmetric urea intermediate(s) into a quinazolinedione compound(s) of formula (4) in the presence of a base(s); and N-alkylating quinazolinedione ring amide of the obtained quinazolinedione compounds with N-alkylation agents. This production method is an industrially applicable method for producing phenylalanine derivatives having a quinazolinedione skeleton, which are compounds highly useful as drugs having α 4 integrin inhibiting activity. In the formulae (1) and (5), R1 represents a phenyl group having a substituent(s) and the like, R2 represents an alkyl group and the like, R3 represents a dialkylamino group and the like, and R4 represents an alkyl group and the like.

  本发明提供了一种制备具有公式（5）的喹唑啉二酮环的苯丙氨酸衍生物的方法，包括以下步骤：将公式（1）的酰基苯丙氨酸衍生物与羰基引入试剂和蒽酸衍生物反应，形成不对称脲中间体；在碱的存在下将不对称脲中间体制成公式（4）的喹唑啉二酮化合物；并用N-烷基化试剂对所得喹唑啉二酮化合物的喹唑啉二酮环酰胺进行N-烷基化。该制备方法是一种工业上适用的制备苯丙氨酸衍生物的方法，这些衍生物具有α4整合素抑制活性，是非常有用的药物化合物。在公式（1）和（5）中，R1代表具有取代基等的苯基，R2代表烷基等，R3代表二烷基胺基等，R4代表烷基等。
• Phenylalanine derivatives
  申请人：Sagi Kazuyuki

  公开号：US20050101779A1

  公开（公告）日：2005-05-12

  The present invention relates to the following phenylalanine derivatives or analogues thereof having an antagonistic activity to α4 integrin and therapeutic agents for various diseases concerning α4 integrin.

  本发明涉及以下苯丙氨酸衍生物或其类似物，具有对α4整合素的拮抗活性以及与α4整合素有关的各种疾病的治疗剂。
• METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF DERIVATIVES
  申请人：KATAOKA Noriyasu

  公开号：US20090318688A1

  公开（公告）日：2009-12-24

  A method for preparing a phenylalanine derivative having a quinazoline-dione ring represented by the following formula (1) or a pharmaceutically acceptable salt thereof, comprising the following steps (a), (b) and (c): (a) reacting an acyl phenylalanine derivative represented by the following formula (2): with a carbonyl group-introducing reagent and a specific anthranilic acid derivative to thus form the corresponding carboxy-asymmetric urea derivative; (b) converting the carboxy-asymmetric urea derivative into the corresponding quinazoline-dione derivative in the presence of a carboxyl group-activating agent: (c) if desired, substituting an N-alkyl group for the hydrogen atom bonded to the nitrogen atom present in the quinazoline-dione ring of the quinazoline-dione derivative using an N-alkylation agent and then deprotecting the resulting product, when the substituent R3′ which is a group corresponding to R3 is protected. According to this method, there can be obtained a phenylalanine derivative having a quinazoline-dione skeleton in a industrially favorably high yield.

  一种制备具有喹唑啉二酮环的苯丙氨酸衍生物或其药学上可接受的盐的方法，其由以下步骤(a)、(b)和(c)组成：(a)用羰基基团引入试剂和特定的蒽酸衍生物反应，以形成相应的羧基-不对称脲衍生物，所述脲衍生物由以下式(2)所表示的酰基苯丙氨酸衍生物反应而成：(b)在羧基活化剂的存在下，将羧基-不对称脲衍生物转化为相应的喹唑啉二酮衍生物；(c)如果需要，在R3'是被保护的基团对应的R3时，使用N-烷基化试剂将取代喹唑啉二酮环中氮原子上的氢原子的N-烷基基团替换，并去保护所得产物。根据该方法，可以得到一个工业上有利的高产率的具有喹唑啉二酮骨架的苯丙氨酸衍生物。
• METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF THE DERIVATIVES
  申请人：KATAOKA Noriyasu

  公开号：US20110313154A1

  公开（公告）日：2011-12-22

  A method for preparing a phenylalanine derivative having a quinazoline-dione ring represented by the following formula (1) or a pharmaceutically acceptable salt thereof, comprising the following steps (a), (b) and (c): (a) reacting an acyl phenylalanine derivative represented by the following formula (2): with a carbonyl group-introducing reagent and a specific anthranilic acid derivative to thus form the corresponding carboxy-asymmetric urea derivative; (b) converting the carboxy-asymmetric urea derivative into the corresponding quinazoline-dione derivative in the presence of a carboxyl group-activating agent: (c) if desired, substituting an N-alkyl group for the hydrogen atom bonded to the nitrogen atom present in the quinazoline-dione ring of the quinazoline-dione derivative using an N-alkylation agent and then deprotecting the resulting product, when the substituent R3′ which is a group corresponding to R3 is protected. According to this method, there can be obtained a phenylalanine derivative having a quinazoline-dione skeleton in a industrially favorably high yield.

  一种制备具有喹唑啉二酮环的苯丙氨酸衍生物或其药学上可接受的盐的方法，其表示为以下公式（1），包括以下步骤（a）、（b）和（c）： （a）将以下公式（2）所表示的酰基苯丙氨酸衍生物与羰基引入试剂和特定的蒽酰氨基酸衍生物反应，从而形成相应的羧基不对称脲衍生物； （b）在羧基活化剂的存在下，将羧基不对称脲衍生物转化为相应的喹唑啉二酮衍生物； （c）如果需要，当保护基R3'对应于R3的基团受保护时，使用N-烷基化试剂将连接在喹唑啉二酮环中氮原子上的氢原子取代为N-烷基基团，然后去保护所得产物。通过该方法，可以在工业上获得具有喹唑啉二酮骨架的苯丙氨酸衍生物，且收率高。
• PHARMACEUTICAL PREPARATION COMPRISING PHENYLALANINE DERIVATIVE
  申请人：Ajinomoto Co., Inc.

  公开号：EP2554169A1

  公开（公告）日：2013-02-06

  The disclosed pharmaceutical preparation comprises a compound represented by the chemical formula (A) or a pharmaceutically acceptable salt thereof, which is dispersed in a matrix consisting of a water-soluble high molecular weight substance; and Crospovidone: The pharmaceutical preparation is excellent in the solubility and the storage stability even if the amount of the compound or the salt included in each individual dosage unit is increased.

  所公开的药物制剂包括由化学式（A）代表的化合物或其药学上可接受的盐，该化合物分散在由水溶性高分子量物质和克罗波维酮组成的基质中： 即使增加每个剂量单位所含化合物或盐的量，该药物制剂的溶解性和储存稳定性也非常好。